Will R&D Make Merck Hot Again?
Will R&D Make Merck Hot Again?
The drug giant gets out of the prescription business and bets it all on science.
Cracking the cancer code
Cracking the cancer code
Whether a tumor invades the lung or breast is beside the point. Its genetic activity will dictate how to attack it
Report raps drug firms' 'post-approval' studies
Report raps drug firms’ ‘post-approval’ studies
Drug manufacturers spent $1.5 billion in 2000 to test medicines already approved by the Food and Drug Administration primarily so they could make new marketing claims to sell their products, industry specialists said this week. Critics say the trend inflates health care costs while undercutting the integrity of research.
Of Clones and Clowns
Of Clones and Clowns A distinguished molecular biologist discusses the “cloning circus” and the damage it is doing to serious research
Legal Circumvention
Legal Circumvention
Molecular switches provide a route around existing gene patents
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments